跳至主要内容
临床试验/NCT05000931
NCT05000931已完成不适用

A Pivotal, Prospective, Multi-center, Open-label Study Evaluating the Safety and Effectiveness of the CochlearTM Osia® 2 System in a Pediatric Population.

Cochlear7 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年1月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Cochlear
入组人数
50
试验地点
7
主要终点
Number of Adverse Events Quantified by Type and Severity Between Implantation and 6-months Post-surgery.

研究概览

简要总结

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD).Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Thus the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.

详细描述

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD). Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Due to the success of the Osia 2 system in the United States within the currently indicated patient population, clinical providers have since requested the ability to use the Osia 2 system in children aged 11 years and younger who meet the audiometric requirements. As the Osia 2 system is based on existing bone conduction and cochlear implant technologies which each possess a younger age of implantation requirement (5 years for bone conduction and 9 months for cochlear implantation), the current proposal is to align the age at implantation requirement with existing surgical bone conduction technology such as the Baha Connect and Baha Attract Systems to 5 years of age. Therefore, the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
5 Years 至 11 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Subjects aged 5 to 11 years of age with the following audiometric criterion:
  • •A conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 55 dB HL. OR
  • •A profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at 0.5, 1, 2, and 3 kHz).
  • •Prior experience with amplified sound through properly fitted amplification device such as a hearing aid, a CROS device, or a bone conduction device on a softband or sound arc.
  • •Parent or legal guardian who is willing and able to provide written informed consent for the study participant.
  • •Note: Subjects may include individuals seeking new implantation unilaterally (in one ear) or individuals already implanted with a bone-anchored device seeking a second-side implant (sequential bilateral)

排除标准

  • •Insufficient bone quality or quantity to support implantation of both the BI300 Implant and the OSI200 Implant.
  • •Chronic or non-revisable vestibular or balance disorders that could prevent benefit from the device, as determined by the investigator.
  • •Abnormally progressive hearing loss.
  • •Evidence that hearing loss is bilateral retro cochlear or bilateral central origin.
  • •Evidence of conditions that would prevent speech recognition improvement as determined by the investigator.
  • •Skin or scalp conditions that may preclude attachment of the Sound Processor or that may interfere with the use of the Sound Processor.
  • •Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
  • •Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
  • •Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation.
  • •Currently participating, or participated within the last 30 days, in another clinical investigation involving an investigational drug or device that could impact the safety or effectiveness of the Osia 2 system as determined by the investigator.
  • •Individuals undergoing simultaneous single-stage aural atresia or microtia repair due to the increased risk of skin complications associated with ear reconstruction.

研究组 & 干预措施

To demonstrate the safety of the Osia 2 System in a pediatric population aged 5 - 11 years.

Experimental

干预措施: Osia 2 System (Device)

结局指标

主要结局

Number of Adverse Events Quantified by Type and Severity Between Implantation and 6-months Post-surgery.

时间窗: From implantation to 6 months post-surgery

Adverse events were reported from the time of implantation through 6-months.

次要结局

  • Change in Sentence Recognition in Noise Using the Bramford Kowal Bench Speech-In-Noise (BKB-SIN) From Unaided Baseline to Aided 6-months Post-surgery.(Baseline before surgery, 6 months post-surgery)
  • Change in Word Recognition Using Consonant Nucleus Consonant (CNC) Words Presented in Quiet From Unaided Baseline to Aided 6-months Post-surgery.(Baseline before surgery, 6 months post-surgery)
  • Change From Baseline to 4-weeks Post-surgery in Unaided Bone Conduction Thresholds.(Baseline before surgery, 4 weeks post-surgery)
  • Change From Baseline to 6-months Post-surgery in SSQ (Speech, Spatial and Qualities of Hearing Scale) Parent Questionnaire(Baseline before surgery, 6 months post-surgery)

研究者

发起方
Cochlear
申办方类型
Industry
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验

招募中
2 期
Pembrolizumab and EV With Radiation Therapy for MIBC PatientsMuscle invasive bladder cancerBladder Cancer,Bladder preservation,Radiation therapy,ImmunotherapyD001749
JPRN-jRCT2051230071Kobayashi Takashi30
招募中
2 期
A Phase II, Open-label, Multicenter, Translational Study for Biomarkers of Eribulin Mesylate: Evaluation of the Utility of Monitoring Epithelial-to-Mesenchymal Transition (EMT) Markers on Tumor Cells in the Malignant Plural Effusion of Patients with Metastatic Breast CancerMetastatic Breast Cancer
JPRN-UMIN000022362Shizuoka Cancer Center48
进行中(未招募)
1 期
A Study of Isatuximab-based Therapy in Participants with LymphomaymphomaMedDRA version: 20.0Level: PTClassification code 10025310Term: LymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-002442-37-NLSanofi-aventis recherche & developpement145
进行中(未招募)
1 期
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination with Atezolizumab in Patients with Advanced MalignancieseoplasmMedDRA version: 21.1Level: PTClassification code 10028980Term: NeoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-000390-67-GRSanofi-aventis recherche & développement385
进行中(未招募)
1 期
A Study of Isatuximab-based Therapy in Participants with LymphomaymphomaMedDRA version: 20.0Level: PTClassification code 10025310Term: LymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-002442-37-PTSanofi-aventis recherche & developpement145
Osia 2 Pediatric Expansion Study | 临床试验